<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">systhiper-336</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КАРДИОНЕВРОЛОГИЯ</subject></subj-group></article-categories><title-group><article-title>Значение артериальной гипертензии в развитии поражения головного мозга - от легких когнитивных нарушений к деменции</article-title><trans-title-group xml:lang="en"><trans-title>Place of arterial hypertension in brain lesion development - from minor cognitive disorders to dementia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шишкова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shishkova</surname><given-names>V. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГУЗ Центр патологии речи и нейрореабилитации, Москва</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>11</volume><issue>1</issue><fpage>45</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шишкова В.Н., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Шишкова В.Н.</copyright-holder><copyright-holder xml:lang="en">Shishkova V.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/336">https://www.syst-hypertension.ru/jour/article/view/336</self-uri><abstract><p>Проблема нарушений когнитивных функций у пациентов с соматическими заболеваниями сегодня занимает ведущую позицию, поскольку представляют собой одно из наиболее распространенных проявлений органического поражения головного мозга. Роль артериальной гипертензии (АГ) в формировании когнитивных нарушений (КН) была показана в крупных эпидемиологических исследованиях. КН выявляются у 73% пациентов как среднего, так и пожилого возраста с длительностью АГ более 5 лет. Раннее выявление потенциально излечимых когнитивных расстройств - одна из важных задач современного врача-терапевта, кардиолога, эндокринолога, семейного врача, поскольку пациенты на ранних стадиях КН составляют большинство из обратившихся за помощью. В современном мире часто действия врачей первичного звена являются определяющими в прогнозе развития деменции, так как выявление ранних недементных форм КН и своевременное адекватное лечение сердечно-сосудистой патологии, в первую очередь АГ, часто вполне достаточно, чтобы выраженность КН у пациента значимо уменьшилась, а деменция никогда не наступила.</p></abstract><trans-abstract xml:lang="en"><p>He problem of cognitive impairment in patients with somatic diseases today occupies a leading position, as it represents one of the most widespread manifestations of organic brain damage. The role of arterial hypertension(AH) in the formation of cognitive impairment (CI) has been shown in large epidemiological studies. CI detected in 73% of patients of both middle and senior age with hypertension duration of more than 5 years. Early detection of potentially treatable cognitive disorders is one of the most important tasks of the modern practitioner, cardiologist, endocrinologist, family doctor, as the patients in the early stages of CI constitute the majority of people seeking help. In today's world, primary care physicians' actions are often crucial in the prediction of dementia, since the detection of early forms of non-dementia CI and timely and adequate treatment of cardiovascular disease, especially hypertension, is often enough for the severity of the CI patients was significantly decreased, and dementia never came.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>когнитивные нарушения</kwd><kwd>деменция</kwd><kwd>артериальная гипертензия</kwd><kwd>лозартан</kwd><kwd>амлодипин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cognitive disorders</kwd><kwd>dementia</kwd><kwd>arterial hypertension</kwd><kwd>losartan</kwd><kwd>amlodipine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. Методическое пособие для врачей. М., 2005.</mixed-citation><mixed-citation xml:lang="en">Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. Методическое пособие для врачей. М., 2005.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ferri C.P, Prince M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112-7.</mixed-citation><mixed-citation xml:lang="en">Ferri C.P, Prince M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112-7.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Суслина З.А., Варакин Ю.Я., Верещагин Н.В. Сосудистые заболевания головного мозга: Эпидемиология. Основы профилактики. М.: МЕДпресс - информ, 2009.</mixed-citation><mixed-citation xml:lang="en">Суслина З.А., Варакин Ю.Я., Верещагин Н.В. Сосудистые заболевания головного мозга: Эпидемиология. Основы профилактики. М.: МЕДпресс - информ, 2009.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев Е.И., Боголепова А.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М.: МЕДпреcс - информ, 2013.</mixed-citation><mixed-citation xml:lang="en">Гусев Е.И., Боголепова А.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М.: МЕДпреcс - информ, 2013.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.</mixed-citation><mixed-citation xml:lang="en">Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс - информ, 2010.</mixed-citation><mixed-citation xml:lang="en">Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс - информ, 2010.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Яхно Н.Н. Когнитивные расстройства в неврологической клинике. Неврол. журн. 2006; 11 (Прил. 1): 4-12.</mixed-citation><mixed-citation xml:lang="en">Яхно Н.Н. Когнитивные расстройства в неврологической клинике. Неврол. журн. 2006; 11 (Прил. 1): 4-12.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Petersen R.S, Smith G.E, Waring S.C et al. Mild cognitive impairement: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.</mixed-citation><mixed-citation xml:lang="en">Petersen R.S, Smith G.E, Waring S.C et al. Mild cognitive impairement: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Int Med 2004; 256: 183-94.</mixed-citation><mixed-citation xml:lang="en">Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Int Med 2004; 256: 183-94.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Дамулин И.В. Легкие когнитивные нарушения. Cons. Med. 2004; 2: 138-41.</mixed-citation><mixed-citation xml:lang="en">Дамулин И.В. Легкие когнитивные нарушения. Cons. Med. 2004; 2: 138-41.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Преображенская И.С. Легкие и умеренные когнитивные нарушения - клинические проявления, этиология, патогенез, возможности использования ноотропной терапии. Спецвыпуск: Психиатрия. Неврология. Фарматека, 2013; 4: 14-8.</mixed-citation><mixed-citation xml:lang="en">Преображенская И.С. Легкие и умеренные когнитивные нарушения - клинические проявления, этиология, патогенез, возможности использования ноотропной терапии. Спецвыпуск: Психиатрия. Неврология. Фарматека, 2013; 4: 14-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Elias M.F, Wolf P.A, D`Agostino et al. Untreated blood pressure level is inversely reated to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138 (6): 353-64.</mixed-citation><mixed-citation xml:lang="en">Elias M.F, Wolf P.A, D`Agostino et al. Untreated blood pressure level is inversely reated to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138 (6): 353-64.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tzourio C, Dufouil C, Ducimetiere P et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 1999; 53 (9): 1948-52.</mixed-citation><mixed-citation xml:lang="en">Tzourio C, Dufouil C, Ducimetiere P et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 1999; 53 (9): 1948-52.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12 (1): 33-9.</mixed-citation><mixed-citation xml:lang="en">Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12 (1): 33-9.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Launer L.J, Masaki K, Petrovitch H et al. The association between midlife blood pressure level and late - life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274 (23): 1846-51.</mixed-citation><mixed-citation xml:lang="en">Launer L.J, Masaki K, Petrovitch H et al. The association between midlife blood pressure level and late - life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274 (23): 1846-51.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Danlof B, Devereux R.B, Kieldsen S.E et al for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.</mixed-citation><mixed-citation xml:lang="en">Danlof B, Devereux R.B, Kieldsen S.E et al for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sierra C, de la Sierra A. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin - receptor blockers. Curr Opin Nephrol Hypertens 2005; 14: 435-41.</mixed-citation><mixed-citation xml:lang="en">Sierra C, de la Sierra A. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin - receptor blockers. Curr Opin Nephrol Hypertens 2005; 14: 435-41.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hernandez R.H, Armas-Hernandez M.J, Velasco M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10 (6): 409-14.</mixed-citation><mixed-citation xml:lang="en">Hernandez R.H, Armas-Hernandez M.J, Velasco M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10 (6): 409-14.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mancini G.B.J, Michael E Miller, Ward Riley (for the PREVENT Investigators) Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events. Circulation 2000; 102: 1503-10.</mixed-citation><mixed-citation xml:lang="en">Mancini G.B.J, Michael E Miller, Ward Riley (for the PREVENT Investigators) Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events. Circulation 2000; 102: 1503-10.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Forette F, Seux M.L. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in europe (syst - eur) study. Arch Intern Med 2002; 162 (18): 2046-52.</mixed-citation><mixed-citation xml:lang="en">Forette F, Seux M.L. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in europe (syst - eur) study. Arch Intern Med 2002; 162 (18): 2046-52.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lithell H, Hansson L, Skoog I et al for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double - blind intervention trial. Hypertension 2003; 21: 875-6.</mixed-citation><mixed-citation xml:lang="en">Lithell H, Hansson L, Skoog I et al for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double - blind intervention trial. Hypertension 2003; 21: 875-6.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.</mixed-citation><mixed-citation xml:lang="en">Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Diener H.C, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double - blind, controlled trial comparing two antithrombotic regimens (a fixed - dose combination of extended - release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes trial (PRoFESS). Cerebrovasc Dis 2007; 23: 368-80.</mixed-citation><mixed-citation xml:lang="en">Diener H.C, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double - blind, controlled trial comparing two antithrombotic regimens (a fixed - dose combination of extended - release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes trial (PRoFESS). Cerebrovasc Dis 2007; 23: 368-80.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Tedesco M.A, Ratti G, Mennella G et al. Comparison of losartan and hydrochloroth - iazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12: 1130-4.</mixed-citation><mixed-citation xml:lang="en">Tedesco M.A, Ratti G, Mennella G et al. Comparison of losartan and hydrochloroth - iazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12: 1130-4.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fogari R, Mugellini A. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertension 2003; 17: 781-5.</mixed-citation><mixed-citation xml:lang="en">Fogari R, Mugellini A. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertension 2003; 17: 781-5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Schrader J et al. Effects of long - term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study) Med Klin (Munich) 2008; 103 (7): 491-9.</mixed-citation><mixed-citation xml:lang="en">Schrader J et al. Effects of long - term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study) Med Klin (Munich) 2008; 103 (7): 491-9.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hanon O. Effects of Antihypertensive Therapy on Cognitive Decline in Alzheimer's N Engl J Med 2003; 348: 1333-41.</mixed-citation><mixed-citation xml:lang="en">Hanon O. Effects of Antihypertensive Therapy on Cognitive Decline in Alzheimer's N Engl J Med 2003; 348: 1333-41.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Braszko J. The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. Acta Neirobiol Exp 1996; 56: 49-54.</mixed-citation><mixed-citation xml:lang="en">Braszko J. The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. Acta Neirobiol Exp 1996; 56: 49-54.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Wright J.W, Harding J.W. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimers disease. J Renin Angiotensin Aldosterone Syst 2008; 9: 226-37.</mixed-citation><mixed-citation xml:lang="en">Wright J.W, Harding J.W. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimers disease. J Renin Angiotensin Aldosterone Syst 2008; 9: 226-37.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hanon O, Pequignot R. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006; 24 (10): 2101-7.</mixed-citation><mixed-citation xml:lang="en">Hanon O, Pequignot R. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006; 24 (10): 2101-7.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng F. Adherence and persistence of single - pill ARB/CCB combination therapy compared to multiple - pill ARB/CCB regimens. Curr Med Res Opin 2010; 26 (12): 2877-87.</mixed-citation><mixed-citation xml:lang="en">Zeng F. Adherence and persistence of single - pill ARB/CCB combination therapy compared to multiple - pill ARB/CCB regimens. Curr Med Res Opin 2010; 26 (12): 2877-87.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Coca A. Ambulatory Blood Pressure in Stroke and Cognitive Dysfunction. Curr Hypertens Rep 2013; 15: 150-9.</mixed-citation><mixed-citation xml:lang="en">Coca A. Ambulatory Blood Pressure in Stroke and Cognitive Dysfunction. Curr Hypertens Rep 2013; 15: 150-9.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
